S'abonner

Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study - 25/03/21

Doi : 10.1016/S1473-3099(20)30984-1 
Nicholas G Davies, DPhil a, , Rosanna C Barnard, PhD a, Christopher I Jarvis, PhD a, Timothy W Russell, PhD a, Malcolm G Semple, ProfPhD b, c, Mark Jit, ProfPhD a, W John Edmunds, ProfPhD a
on behalf of the

Centre for Mathematical Modelling of Infectious Diseases COVID-19 Working Group

  Members are listed in the Supplementary Material)

and

ISARIC4C investigators

  Members are listed in the Supplementary Material)

a Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK 
b National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK 
c Department of Respiratory Medicine, Alder Hey Children’s Hospital, Liverpool, UK 

* Correspondence to: Dr Nicholas G Davies, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK Department of Infectious Disease Epidemiology London School of Hygiene & Tropical Medicine London WC1E 7HT UK

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Background

A second wave of COVID-19 cases in autumn, 2020, in England led to localised, tiered restrictions (so-called alert levels) and, subsequently, a second national lockdown. We examined the impact of these tiered restrictions, and alternatives for lockdown stringency, timing, and duration, on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and hospital admissions and deaths from COVID-19.

Methods

We fit an age-structured mathematical model of SARS-CoV-2 transmission to data on hospital admissions and hospital bed occupancy (ISARIC4C/COVID-19 Clinical Information Network, National Health Service [NHS] England), seroprevalence (Office for National Statistics, UK Biobank, REACT-2 study), virology (REACT-1 study), and deaths (Public Health England) across the seven NHS England regions from March 1, to Oct 13, 2020. We analysed mobility (Google Community Mobility) and social contact (CoMix study) data to estimate the effect of tiered restrictions implemented in England, and of lockdowns implemented in Northern Ireland and Wales, in October, 2020, and projected epidemiological scenarios for England up to March 31, 2021.

Findings

We estimated a reduction in the effective reproduction number (Rt) of 2% (95% credible interval [CrI] 0–4) for tier 2, 10% (6–14) for tier 3, 35% (30–41) for a Northern Ireland-stringency lockdown with schools closed, and 44% (37–49) for a Wales-stringency lockdown with schools closed. From Oct 1, 2020, to March 31, 2021, a projected COVID-19 epidemic without tiered restrictions or lockdown results in 280 000 (95% projection interval 274 000–287 000) hospital admissions and 58 500 (55 800–61 100) deaths. Tiered restrictions would reduce hospital admissions to 238 000 (231 000–245 000) and deaths to 48 600 (46 400–50 700). From Nov 5, 2020, a 4-week Wales-type lockdown with schools remaining open—similar to the lockdown measures announced in England in November, 2020—was projected to further reduce hospital admissions to 186 000 (179 000–193 000) and deaths to 36 800 (34 900–38 800). Closing schools was projected to further reduce hospital admissions to 157 000 (152 000–163 000) and deaths to 30 300 (29 000–31 900). A projected lockdown of greater than 4 weeks would reduce deaths but would bring diminishing returns in reducing peak pressure on hospital services. An earlier lockdown would have reduced deaths and hospitalisations in the short term, but would lead to a faster resurgence in cases after January, 2021. In a post-hoc analysis, we estimated that the second lockdown in England (Nov 5–Dec 2) reduced Rt by 22% (95% CrI 15–29), rather than the 32% (25–39) reduction estimated for a Wales-stringency lockdown with schools open.

Interpretation

Lockdown measures outperform less stringent restrictions in reducing cumulative deaths. We projected that the lockdown policy announced to commence in England on Nov 5, with a similar stringency to the lockdown adopted in Wales, would reduce pressure on the health service and would be well timed to suppress deaths over the winter period, while allowing schools to remain open. Following completion of the analysis, we analysed new data from November, 2020, and found that despite similarities in policy, the second lockdown in England had a smaller impact on behaviour than did the second lockdown in Wales, resulting in more deaths and hospitalisations than we originally projected when focusing on a Wales-stringency scenario for the lockdown.

Funding

Horizon 2020, UK Medical Research Council, and the National Institute for Health Research.

Le texte complet de cet article est disponible en PDF.

Plan


© 2021  The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 21 - N° 4

P. 482-492 - avril 2021 Retour au numéro
Article précédent Article précédent
  • SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study
  • Hossein Poustchi, Maryam Darvishian, Zahra Mohammadi, Amaneh Shayanrad, Alireza Delavari, Ayad Bahadorimonfared, Saeid Eslami, Shaghayegh Haghjooy Javanmard, Ebrahim Shakiba, Mohammad Hossein Somi, Amir Emami, Nader Saki, Ahmad Hormati, Alireza Ansari-Moghaddam, Majid Saeedi, Fatemeh Ghasemi-Kebria, Iraj Mohebbi, Fariborz Mansour-Ghanaei, Manoochehr Karami, Hamid Sharifi, Farhad Pourfarzi, Nasrollah Veisi, Reza Ghadimi, Sareh Eghtesad, Ahmadreza Niavarani, Ali Ali Asgari, Anahita Sadeghi, Majid Sorouri, Amir Anushiravani, Mohammad Amani, Soudeh Kaveh, Akbar Feizesani, Payam Tabarsi, Hossein Keyvani, Melineh Markarian, Fatemeh Shafighian, Alireza Sima, Alireza Sadjadi, Amir Reza Radmard, Ali H Mokdad, Maryam Sharafkhah, Reza Malekzadeh
| Article suivant Article suivant
  • Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
  • Andrew J Pollard, Odile Launay, Jean-Daniel Lelievre, Christine Lacabaratz, Sophie Grande, Neil Goldstein, Cynthia Robinson, Auguste Gaddah, Viki Bockstal, Aurelie Wiedemann, Maarten Leyssen, Kerstin Luhn, Laura Richert, Christine Bétard, Malick M Gibani, Elizabeth A Clutterbuck, Matthew D Snape, Yves Levy, Macaya Douoguih, Rodolphe Thiebaut, EBOVAC2 EBL2001 study group, Christopher McShane, Benoit Callendret, Stephanie Dincq, Camille Ferrault, Siew Pin Chai, Maire Paule Gyselen, Marleen van Looveren, Sylvia van Ballert, Tinne de Cnodder, Len Roza, Chiara Forcheh, Kate Stevens, Carmela Mastrandrea, Sanne de Ridder, Rachana Gundluru, Nathalie Swales, Vanessa Errijegers, Wouter Willems, Veronika Roorda, Nicola Orzabal, Magdalena Assenberg, Karine Vialatte, Frédéric Remblier, Elodie Porcar, Anton Ottavi, Eugénie Destandau, Christine Schwimmer, Laetitia Moinot, Cédrick Wallet, Florence Allais, Hélène Savel, Naouel Nedjaai, Anaïs Maugard, Nehza Lenzi, Pierre Loulergue, Mathilde Bahuaud, Fabrice Lainé, Bruno Laviolle, Nolwenn Boissel, Elise Thébault, David Vallée, Jean-François Nicolas, Sophie Gilbert, Karima Dahel, Karen Sagorny, Frédéric Lucht, Stéphane Paul, Alice Haccourt Chanavat, Florent Charra, Catherine Mutter, Monique Lambour, Caroline Muller, Anne Hutt-Clauss, Olivia Aranda, Louis Bernard, Valérie Gissot, Marie-Charlotte Hallouin-Bernard, Alain Goudeau, Steve Suzzoni, Eva Auostin, Lysiane Brick, Jose-Luis Lopez-Zaragoza, Giovanna Melic, Murial Carvalho, Chrystel Chesnel, Hakim Hocini, Aurélie Wiedemann, Laurent Hanot, Véronique Rieux, Adeep Puri, Temitope Adeloye, Malcolm Boyce, Jeremy Dennison, Inge Loewenstein, Omar Sahgal, Frans van den Berg, Wendy Calvert, Mary Faldon, Bruce McClain, Marie-Lousie Newell, Geert Molenberghs

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.